The Impact of Periodontal Health Interventions on the Risk of Ischemic Stroke: A Systematic Review and Meta-Analysis.

Int J Dent HygApr 20, 2026 (epub)
Clinical ResearchCardiologyPreventive Medicine / Public Health

Jorge Moldes, Joao Botelho, Manuel Rodríguez-Yáñez et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the impact of periodontal health interventions on the risk of first-ever ischemic stroke, analyzing data from seven studies with 1,886,947 participants. The findings indicated that these interventions were associated with a lower risk of ischemic stroke, with a hazard ratio of 0.88. Notably, tooth scaling showed a stronger association with a hazard ratio of 0.84.

Key findings

  • Periodontal interventions were linked to a lower risk of ischemic stroke (HR: 0.88 [0.81-0.95]).
  • Tooth scaling specifically was associated with a reduced risk of ischemic stroke (HR: 0.84 [0.76-0.92]).
  • The review included seven studies with a total of 1,886,947 participants.

Why it matters

These findings highlight the potential importance of maintaining periodontal health as a preventive measure against ischemic stroke, suggesting that dental care may play a significant role in cardiovascular health.

Source

PubMed · PMID 42010754

Published in Int J Dent Hyg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.